Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Incorporation of pathological and (not mandatory) molecular features into the new FIGO 2023 staging system has generated some controversy. Several validations have been published recently that demonstrated the higher prognostic precision of FIGO 2023 compared to the previous FIGO 2009 scheme. In the present article, the authors want to respond to some concerns that were raised by some pathologists and clinicians.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejca.2024.115115 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of diagnostic laparoscopy on resectability and treatment strategy in FIGO III-IV ovarian cancer.
Arch Gynecol Obstet
September 2025
Department of Obstetrics and Gynecology, University Medical Center Freiburg, Freiburg, Germany.
Objective: To investigate the clinical utility of diagnostic laparoscopy in guiding treatment strategy and surgical outcomes for patients with advanced-stage ovarian cancer, specifically regarding operability assessment and the likelihood of complete cytoreduction.
Methods: This retrospective cohort study analyzed 183 patients with histologically confirmed International Federation of Gynecology and Obstetrics (FIGO) stage III-IV ovarian cancer treated with curative intent between January 2018 and December 2023 at a tertiary referral center. Patients were divided into two groups: those who underwent diagnostic laparoscopy prior to primary treatment (n = 80) and those managed without laparoscopy (n = 103).
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer.
ESMO Open
September 2025
Unit of Oncological Gynecology, Women's Children's and Public Health Department, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy. Electronic address: https://twitter.com/camillanero.
Background: The No Specific Molecular Profile (NSMP) subtype accounts for ∼30%-40% of endometrial cancer (EC), comprising a heterogeneous group of EC.
Patients And Methods: The primary outcome of this study was the prevalence of actionable genomic alterations in NSMP EC, classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of molecular Targets (ESCAT). Oncogenic and likely oncogenic alterations, pathways, and co-mutation patterns were reported.
Young Women With Endometrial Cancer: A Portuguese Perspective.
Cancer Diagn Progn
September 2025
Gynecology Department, Instituto Português de Oncologia Francisco Gentil de Lisboa, Lisbon, Portugal.
Background/aim: Endometrial cancer (EC) is rare in premenopausal women. The aim of this study was to describe the demographic, clinical and pathological characteristics and compare survival in the light of pathological aspects of EC in young women.
Patients And Methods: We performed a retrospective observational cohort study, analyzing data from 29 women up to 45 years of age diagnosed between 2003 and 2023 at our Institution.
Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial.
Trials
September 2025
Independent Laboratory of Translational Medicine, Chair of Medical Genetics, Medical University of Lublin, Lublin, Poland.
The management of advanced ovarian cancer has significantly developed with the integration of bevacizumab into standard therapeutic regimens. While the efficacy of bevacizumab has been established in trials such as GOG218, ICON7, and PAOLA-1, there remains a gap in understanding the advantages of the 7.5 mg/kg dose over the 15 mg/kg regimen.
View Article and Find Full Text PDFDoes BRCA Mutation Status Influence Ovarian Cancer Onset Timing and Patients' Treatment Outcomes?
Genes (Basel)
July 2025
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland.
Background/objectives: Mutations in the and genes are well-known risk factors for ovarian cancer. They are also associated with response to platinum-based chemotherapy; however, their definitive impact on patient prognosis remains not fully understood. This study aimed to investigate the influence of mutation status on the age of ovarian cancer onset and on treatment outcomes in patients with high-grade serous ovarian cancer.
View Article and Find Full Text PDF